Sujata B. Walunj

This study uses deep learning and physics-based modeling to engineer a CD27 variant that improves the efficacy of CD70-targeting CAR T-cells across multiple cancer models.

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

The paper identifies small molecules that inhibit nuclear import in apicomplexan parasites, showing efficacy against both rapidly dividing and differentiated stages.